A novel CCR5-specific pharmacodynamic assay in whole blood using phosphoflow cytometry highlights different ligand-dependent responses but similar properties of antagonists in CD8+ and CD4+ T lymphocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 3, 2008, Pages 926-933

  Dahl, Martin E ^a,b   Berson, Amy ^a   Lora, Jose ^a   Fuentes, Maria ^a  

^a Inflammation   (United States)

^b MS R7 201 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; MARAVIROC; SCHERING X; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG TARGETING; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; IN VIVO STUDY; LIGAND BINDING; LYMPHOCYTE SUBPOPULATION; MACACA; NONHUMAN; PHOSPHOFLOW CYTOMETRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHESUS MONKEY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG MONITORING; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MACACA; MACACA MULATTA; METHODS; PHARMACOKINETICS; PHOSPHORYLATION; RECEPTORS, CCR5;

EID: 57349120616     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.142695     Document Type: Article

References (26)

1. Böhm SK, Grady EF, and Bunnett NW (1997) Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J 322:1-18.
2. Brady KA, Berry S, Gupta R, Weiner M, and Turner BJ (2005) Seasonal variation in undiagnosed HIV infection on the general medicine and trauma services of two urban hospitals. J Gen Intern Med 20:324-330.
3. Charo IF and Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. New Engl J Med 354:610-621.
4. Desmetz C, Lin YL, Mettling C, Portalès P, Rabesandratana H, Clot J, and Corbeau P (2006) The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density. Immunology 119:551-561.
5. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 Activity. Antimicrob Agents Chemother 49:4721-4732.
6. Esté JA and Telenti A (2007) HIV entry inhibitors. Lancet 370:81-88.
7. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, and Caron MG (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27:107-144.
8. + T cells. J Exp Med 194:1711-1719.
9. Heredia A, Gilliam B, DeVico A, Le N, Bamba D, Flinko R, Lewis G, Gallo RC, and Redfield RR (2007) CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. AIDS 21:1317-1322.
10. International Union of Immunological Societies/World Health Organization Subcommittee on Chemokine Nomenclature (2003) Chemokine/chemokine receptor nomenclature. Cytokine 21:48-49.
11. Krutzik PO, Clutter MR, and Nolan GP (2005) Coordinate analysis of murine immune cell surface markers and intracellular phosphoproteins by flow cytometry. J Immunol 175:2357-2365.
12. Krutzik PO, Crane JM, Clutter MR, and Nolan GP (2008) High-content single-cell drug screening with phosphospecific flow cytometry. Nat Chem Biol 4:132-142.
13. Krutzik PO, Irish JM, Nolan GP, and Perez OD (2004) Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 110:206-221.
14. Lefkowitz RJ and Shenoy SK (2005) Transduction of receptor signals by {beta}-arrestins. Science 308:512-517.
15. Maes M, Stevens W, Scharpé S, Bosmans E, De Meyer F, D'Hondt P, Peeters D, Thompson P, Cosyns P, De Clerck L, et al. (1994) Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia 50:821-829.
16. + T cells is a typical feature of natural SIV hosts. Blood 109:1069-1076.
17. Perez OD, Krutzik PO, and Nolan GP (2004) Flow cytometric analysis of kinase signaling cascades. Methods Mol Biol 263:67-94.
18. Pitcher JA, Freedman NJ, and Lefkowitz RJ (1998) G protein-coupled receptor kinases. Annu Rev Biochem 67:653-692.
19. Pollok-Kopp B, Schwarze K, Baradari VK, and Oppermann M (2003) Analysis of ligand-stimulated CC chemokine receptor 5 (CCR5) phosphorylation in intact cells using phosphosite-specific antibodies. J Biol Chem 278:2190-2198.
20. Premont RT and Gainetdinov RR (2007) Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69:511-534.
21. + T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis 181:927-932.
22. Samson M, Labbe O, Mollereau C, Vassart G, and Parmentier M (1996) Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35:3362-3367.
23. + T cells differently expressing three cytolytic effector molecules. J Immunol 177:4330-4340.
24. + T cells from a memory to memory/effector phenotype. J Immunol 168:5538-5550.
25. Tomkowicz B, Lee C, Ravyn V, Cheung R, Ptasznik A, and Collman RG (2006) The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages. Blood 108:1145-1150.
26. Vierboom MP, Zavodny PJ, Chou CC, Tagat JR, Pugliese-Sivo C, Strizki J, Steensma RW, McCombie SW, Celebi-Paul L, Remarque E, et al. (2005) Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum 52:627-636.